Highlights

  • Amplia Therapeutics (ASX:ATX) is developing the FAK inhibitor narmafotinib for cancer treatment.
  • The ACCENT pancreatic cancer study reported a 36% confirmed objective response rate.
  • The company signed a collaboration with Eli Lilly to assess narmafotinib with olomorasib in lung cancer.
  • Amplia reported a 2026 financing program of approximately AUD 27.5 million to support drug development.

Amplia Therapeutics Limited (ASX:ATX), an Australian clinical-stage biotechnology company developing oncology medicines, is progressing clinical work on narmafotinib while broadening research into combination treatments. At the time of writing this article on 19 October 2026, its shares were trading at AUD 0.082, up 2.50% during the day’s trading session. The company’s recent work includes planning a later-stage pancreatic cancer study and a clinical collaboration investigating lung cancer. These development programs, alongside research spending and available funding, remain central to assessing its operating position.

Company Business

Amplia focuses on focal adhesion kinase, or FAK, an enzyme involved in signalling pathways affecting cancer cells and their surrounding tissue. Its lead investigational drug, narmafotinib, is being evaluated as an addition to other anticancer treatments, rather than as an approved standalone medicine. The principal clinical program concerns metastatic pancreatic cancer. Research partnerships also cover possible applications in ovarian cancer and other solid tumours. Clinical and regulatory activities involve Australia and the United States, and the company has used contracted manufacturers to prepare clinical supplies.

Recent Development

The Phase 1b/2a ACCENT study evaluated narmafotinib together with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. In its 2026 annual report, Amplia reported a confirmed objective response rate of 36%, median progression-free survival of approximately 7.7 months and median overall survival of 11.1 months. Five complete responses were identified through independent imaging review. These are outcomes from a non-randomised study, so historical chemotherapy comparisons cannot establish a definitive treatment benefit.

The company has been preparing a controlled Phase 2b/3 development approach. Its annual report described engagement with the US Food and Drug Administration about an initial two-dose comparison strategy. A separate pancreatic cancer study, AMPLICITY, stopped recruiting in April 2026 after dose-limiting toxicity associated with the FOLFIRINOX chemotherapy regimen. Amplia stated that the decision shifted attention towards different combination approaches.

In August 2026, Amplia announced a clinical trial collaboration and supply agreement with Eli Lilly and Company. The planned Phase 1b/2b study would investigate narmafotinib alongside olomorasib, a KRAS G12C inhibitor, in advanced non-small-cell lung cancer. The company indicated an intended study start in late 2026, with sites in Australia and the United States. Separate plans involving ovarian cancer also reflect an effort to evaluate narmafotinib beyond its original pancreatic cancer setting.

Financial Performance and Sector Context

Amplia is a development-stage medicine company whose financial performance is primarily shaped by research, clinical trial costs, manufacturing and funding activities, rather than established commercial drug sales. Its annual report recorded financing of approximately AUD 27.5 million from a placement and share purchase plan during the reporting year. The company also received government research and development tax incentive funding. These resources support clinical operations, but further spending will be required to complete larger studies and pursue regulatory applications.

The 2026 annual report also described production of approximately 13 kilograms of narmafotinib active pharmaceutical ingredient under Good Manufacturing Practice conditions. The manufacturing activity was intended to support clinical supply requirements. Across oncology drug development, clinical trial design, patient recruitment, manufacturing consistency and regulatory review are material cost and timing considerations. Data from early-stage studies may help establish research priorities, although later controlled trials are needed to evaluate efficacy and safety more conclusively.

Risks to Consider

Clinical risk remains significant because narmafotinib is investigational and regulatory approval has not been established. The decision to end AMPLICITY recruitment illustrates how combination-drug tolerability can affect study execution. Later-stage trials may involve different patient populations, protocols and endpoints from ACCENT, making earlier observations an uncertain guide to subsequent results. Further risks include delays in recruitment, clinical supply requirements, collaboration execution, cash consumption and potential future financing. Any additional capital raising could change the company’s share count.

What to Watch Next

Operational points to monitor include updates to ACCENT follow-up data, preparations for the planned controlled pancreatic cancer study and regulatory discussions about its design. Progress on the announced Lilly combination study and the proposed ovarian cancer trial will also clarify how the company is allocating clinical resources. Future quarterly cash-flow reports should show how trial expenditure compares with the company’s available funding. Timing of trial initiation and patient recruitment remains subject to clinical and regulatory processes.

Key Insights

Amplia’s current development agenda centres on translating non-randomised ACCENT observations into more rigorous clinical testing while exploring additional cancer indications. Its 2026 funding program and manufacturing work support that agenda, but they do not remove the uncertainties of drug development. The next material evidence will come from trial execution, controlled clinical outcomes, regulatory feedback and updated cash-flow disclosures.